Ling Ma

Dr. Ling Ma


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Molecular Therapy
Verified
Journal Article
Open access
ZXZijie Xu
Zijie Xu
YCYi Chen
Yi Chen
LMLing Ma
Ling Ma
YCYizhang Chen
Yizhang Chen
JLJingya Liu
Jingya Liu
YSYongqian Shu
Yongqian Shu
Exosomes have a crucial role in intercellular communication and mediate interactions between tumor cells and tumor-associated macrophages (TAMs). Exosome-encapsulated non-coding RNAs (ncRNAs) are involved in various physiological processes. Tumor-derived exosomal ncRNAs induce M2 macrophage polarization through signaling pathway activation, signal transduction, and transcriptional and post-transcriptional regulation. Conversely, TAM-derived exosomal ncRNAs promote tumor proliferation, metastasis, angiogenesis, chemoresistance, and immunosuppression. MicroRNAs induce gene silencing by directly targeting mRNAs, whereas lncRNAs and circRNAs act as miRNA sponges to indirectly regulate protein expressions. The role of ncRNAs in tumor-host interactions is ubiquitous. Current research is increasingly focused on the tumor microenvironment. On the basis of the "cancer-immunity cycle" hypothesis, we discuss the effects of exosomal ncRNAs on immune cells to induce T cell exhaustion, overexpression of programmed cell death ligands, and create a tumor immunosuppressive microenvironment. Furthermore, we discuss potential applications and prospects of exosomal ncRNAs as clinical biomarkers and drug delivery systems.

5 July 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
LYLanqing Yang
Lanqing Yang
DLDan Liu
Dan Liu
XFXin Fang
Xin Fang
ZWZiqiang Wang
Ziqiang Wang
YXYue Xing
Yue Xing
BWBing Wu
Bing Wu

19 July 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
YGYuchen Guo
Yuchen Guo
YCYi Chen
Yi Chen
LZLianghui Zhang
Lianghui Zhang
LMLing Ma
Ling Ma
KJKeyu Jiang
Keyu Jiang
LZLingjun Zhu
Lingjun Zhu
Malignant melanoma is an extremely malignant tumor with a high mortality rate and an increasing incidence with a high mutation load. The frequency of mutations in the TERT promoter exceeds the frequency of any known noncoding mutations in melanoma. A growing number of recent studies suggest that the most common mutations in the TERT promoter (ATG start site −124C>T and −146C>T) are associated with increased TERT mRNA expression, telomerase activity, telomere length, and poor prognosis. Recently, it has been shown that TERT promoter mutations are more correlated with the occurrence, development, invasion, and metastasis of melanoma, as well as emerging approaches such as the therapeutic potential of chemical inhibition of TERT promoter mutations, direct telomerase inhibitors, combined targeted therapy, and immunotherapies. In this review, we describe the latest advances in the role of TERT promoter mutations and telomerase in promoting the occurrence, development, and poor prognosis of melanoma and discuss the clinical significance of the TERT promoter and telomerase in the treatment of melanoma.

24 November 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
LMLing Ma
Ling Ma
YLYu Lin
Yu Lin
SSShan-Wen Sun
Shan-Wen Sun
JXJun Xu
Jun Xu
TYTing Yu
Ting Yu
LZLingjun Zhu
Lingjun Zhu

3 December 2023 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
MSMinyue Shou
Minyue Shou
HZHanyu Zhou
Hanyu Zhou
LMLing Ma
Ling Ma

13 March 2019 in Cancer Biology & Therapy
Verified
Journal Article
Open access
LMLing Ma
Ling Ma
JWJia Wei
Jia Wei
GSGloria Su
Gloria Su
JLJiayuh Lin
Jiayuh Lin
SRC and its activated form, phospho-SRC (pSRC), are aberrantly activated in pancreatic cancer and SRC represents a potential target for pancreatic cancer therapy. In this paper, we examined the inhibitory effect of dasatinib, a potent SRC inhibitor in combination with paclitaxel or gemcitabine on human and murine pancreatic cancer cell lines. The results showed that p-SRC can be highly expressed in most human and mouse pancreatic cancer cell lines compared with normal human cell lines and can be induced by paclitaxel or gemcitabine in HPAC cells. Dasatinib can enhance the efficacy of paclitaxel or gemcitabine by reducing the cell viability and inhibiting the cell proliferation. Dasatinib with paclitaxel combination exhibits statistically greater inhibition of the cell migration ability than single agent alone, paclitaxel with gemcitabine or FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) in HAPC, PANC-1, and BXPC-3 human pancreatic cancer cell lines as well as 8–285 APR and 8–365 APR mouse pancreatic cancer cell lines. In addition, dasatinib with gemcitabine combination also showed statistically greater inhibition of cell migration than single agent alone, paclitaxel with gemcitabine, or FOLFIRINOX in HAPC, PANC-1 and 8–285 APR cells. The combination of dasatinib with paclitaxel or gemcitabine also showed greater inhibition of the colony formation ability of pancreatic cancer cells compared with single-agent monotherapy or FOLFIRINOX. Dasatinib with paclitaxel or gemcitabine combination also inhibits p-SRC, p-STAT3, p-AKT, and/or p-ERK in these pancreatic cancer cells. Therefore, our results support that combined dasatinib and paclitaxel or gemcitabine therapy may be a viable therapeutic approach for human pancreatic cancer.